A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Conditions

• Chronic Plaque Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - 70 Years

Healthy Volunteers

Not accepted

Interventions

• Bimekizumab — DRUG
  Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
• Placebo — OTHER
  Subjects will receive injections of Placebo.

Study Details

This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

Key Dates

Start date

Dec 27, 2016

Status verified

Mar 2026

Primary completion

Dec 11, 2017

Completion

Dec 11, 2017

Study Design

Enrollment

49 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Treatment Arm 1
  Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.
• Experimental: Treatment Arm 2
  Subjects randomized in this arm will receive Bimekizumab injections.

Primary Outcome Measure

Change From Baseline in Psoriasis Area and Severity Index (PASI) at Week 28 [ Time Frame: From Baseline to Week 28 ]

Locations (1)

Find similar trials in Bexley, OH